Keyword: Shire

Ahead of an early December shareholder vote on Takeda's Shire buyout, some Takeda investors and insiders are working to gather support against it.

Critics of Takeda’s $62 billion Shire buyout have fretted lately about the company’s hemophilia standing. But immunology is a different story.

Ex-Roche scientists were charged with stealing trade secrets; Astellas invested in gene and cell therapy; Takeda touted growth in key focus areas.

Takeda is eager to close its Shire deal and take the specialty pharma under its wing, but for now it's highlighting a few strengths in its own business.

Amid reports that it will sell Shire's Xiidra and Natpara, Takeda said it may sell SHP647, a phase 3 bowel drug that would overlap its own Entyvio.

Biogen and Eisai defend Alzheimer's drug; Taiho and Servier's Lonsurf shows positive gastric cancer data; J&J pays $2.1 billion for Japan's Ci:z.

Shire just nabbed FDA panel backing for prucalopride, aiming to challenge Allergan and Synergy in the chronic constipation market.

Shire’s $1 billion plasma fractionation plant in Georgia has gone through three owners but is now officially open.

Roche’s Hemlibra officially has the hemophilia indication it’s been waiting for—and that its competitors have been dreading.

It’s no secret that Takeda’s pending Shire megadeal has its critics, and some of them are now demanding behind-the-scenes info to justify the buy.